Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE ALLERGY versus CLARINEX D 24 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE ALLERGY versus CLARINEX D 24 HOUR.
AZELASTINE HYDROCHLORIDE ALLERGY vs CLARINEX D 24 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine with mast cell stabilizing properties; selectively antagonizes histamine H1 receptors, reducing nasal pruritus, sneezing, rhinorrhea, and ocular symptoms.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. Loratadine is a long-acting antihistamine that selectively antagonizes peripheral H1-receptors.
One spray (137 mcg) per nostril twice daily (total 548 mcg/day). Intranasal route.
1 tablet (5 mg desloratadine/120 mg pseudoephedrine) orally once daily
None Documented
None Documented
The terminal elimination half-life is approximately 22 hours (range 16-26 hours) at steady state, supporting twice-daily dosing. The half-life may be prolonged in elderly patients or those with hepatic impairment.
Desloratadine: terminal t1/2 27 hours (range 20-50h) supporting once-daily dosing. Pseudoephedrine: t1/2 5-8 hours (up to 16h in alkaline urine).
Azelastine is primarily eliminated via renal excretion (approximately 75% as metabolites, <10% unchanged) and fecal excretion (approximately 25%) after oral administration. Biliary excretion is minimal.
Desloratadine: ~87% excreted as metabolites (41% urine, 43% feces), <2% unchanged. Pseudoephedrine: ~70-90% excreted unchanged in urine.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination